Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | CXCR1 | P25024 | 5/20 | 0.46 |
| ▸ | CXCR2 | P25025 | 5/20 | 0.46 |
| ▸ | CXCR3 | P49682 | 2/20 | 0.46 |
| ▸ | CCR6 | P51684 | 2/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.45 |
| ▸ | CNR2 | P34972 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CCR4 | P51679 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | LOX | P28300 | 1/20 | 0.42 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CRHBP | P24387 | 1/20 | 0.41 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14904735 | 1.00 | MAPT (0.48) | MAPTCXCR1CXCR2CXCR3CCR6 | |
| SCHEMBL16144713 | 1.00 | MAPT (0.48) | MAPTCXCR1CXCR2CXCR3CCR6 | |
| SCHEMBL7979807 | 0.90 | KMT2A (0.54) | MAPTCNR1CNR2KMT2AALOX5 | |
| SCHEMBL7982334 | 0.90 | KMT2A (0.54) | MAPTCNR1CNR2KMT2AALOX5 | |
| SCHEMBL14905797 | 0.88 | CXCR1 (0.47) | MAPTCXCR1CXCR2KMT2AKDM4E | |
| SCHEMBL18556234 | 0.88 | MAPT (0.43) | MAPTCXCR1CXCR2CXCR3CCR6 | |
| SCHEMBL14904771 | 0.88 | GAA (0.47) | MAPTCXCR1CXCR2CNR1CNR2 | |
| SCHEMBL14894966 | 0.86 | SMN1; SMN2 (0.49) | MAPTCXCR1CXCR2 | |
| SCHEMBL14894965 | 0.86 | SMN1; SMN2 (0.49) | MAPTCXCR1CXCR2 | |
| SCHEMBL11459789 | 0.85 | CNR1 (0.44) | MAPTCXCR1CXCR2CXCR3CCR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9388149-B2 | Disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated diseases | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2016-07-12 | — | — | US | disclosed |
| US-20140296254-A1 | NOVEL DISUBSTITUTED 3,4-DIAMINO-3-CYCLOBUTENE-1,2-DIONE COMPOUNDS FOR USE IN THE TREATMENT OF CHEMOKINE-MEDIATED DISEASES | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2014-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140296254-A1 | NOVEL DISUBSTITUTED 3,4-DIAMINO-3-CYCLOBUTENE-1,2-DIONE COMPOUNDS FOR USE IN THE TREATMENT OF CHEMOKINE-MEDIATED DISEASES | CCL2, CCL11, CCR1 | MAPT 3331/4885CXCR1 11/4885CXCR2 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.